Frontlight ResearchEarly access
CompletedPhase 2
A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine
Key facts
- Who runs it
- Clear Scientific, Inc.
- Where
- Glendale, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 34 people enrolled
- Started
- 5 Feb 2026
- Ended
- 29 Oct 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Methamphetamine
- Sterile Saline
- CS-1103
- Record updated
- 10 November 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Other criteria
- Major Inclusion Criteria:
- Healthy participants aged 18 to 55 years, inclusive
- Meets DSM-5 criteria for methamphetamine use disorder
- Not seeking treatment for methamphetamine use disorder
- Primary route of methamphetamine self-administration must be intravenous or smoking
- Able to abstain from methamphetamine without experiencing severe withdrawal
- A body mass index between 18 to 30 kg/m2, inclusive and a minimum body weight of 56 kg
- Females must not be lactating and must have a negative pregnancy test during screening and admission; Major Exclusion Criteria:
- Estimated glomerular filtration rate <60 mL/min/1.73 m2
- History of cardiovascular disease
- Current moderate to severe use disorder for alcohol, cannabis, cocaine, opioids, or benzodiazepines
- History of any clinically important disease or disorder which, in the opinion of the Investigator, may interfere with safe study participation
Where in United States
- California Clinical Trials Medical GroupGlendale, United States
About the trial
What the trial wants to find out
The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).
The 2 groups in the trial
- PlaceboPlacebo, for comparison
Participants receive methamphetamine HCl (30 mg) followed by placebo (saline).
Treatment: Methamphetamine and Sterile Saline
- ActiveExisting treatment, for comparison
Participants receive methamphetamine HCl (30 mg) followed by one of four doses of CS-1103
Treatment: Methamphetamine and CS-1103
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine
- Record updated
- 10 November 2026